Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries

International Journal of Cancer

Volumn 121, Issue 4, 2007, Pages 825-831

  Goldstein, Alisa M ^a   Chaudru, Valerie ^b   Ghiorzo, Paola ^c   Badenas, Celia ^d   Malvehy, Josep ^d   Pastorino, Lorenza ^c   Laud, Karine ^e   Hulley, Benjamin ^a   Avril, Marie Francoise ^f   Puig Butille, Joan A ^d   Miniere, Annie ^e   Marti, Rosa ^g   Chompret, Agnes ^e   Cuellar, Francisco ^d   Kolm, Isabel ^d   Mila, Montserrat ^d   Tucker, Margaret A ^a   Demenais, Florence ^b   Bianchi Scarra, Giovanna ^c   Puig, Susana ^d   De Paillerets, Brigitte Bressac ^e   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^c UNIVERSITY OF GENOA   (Italy)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Université René Descartes Paris ^*  (France)

^g UNIVERSITY OF LLEIDA   (Spain)

Author keywords

CDKN2A; G101W; MC1R; Melanoma

Indexed keywords

ARTICLE; CDKN2A GENE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; EYE COLOR; FEMALE; FOUNDER EFFECT; FRANCE; G101W GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC VARIABILITY; GEOGRAPHIC ORIGIN; GERM LINE GENE THERAPY; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MC1R GENE; MELANOMA; MULTICENTER STUDY; MUTATOR GENE; NEVUS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SPAIN; UNITED STATES;

ADULT; CASE-CONTROL STUDIES; DYSPLASTIC NEVUS SYNDROME; EYE COLOR; FEMALE; FRANCE; GENE FREQUENCY; GENES, P16; GENOTYPE; HAIR COLOR; HETEROZYGOTE; HUMANS; ITALY; MALE; MELANOMA; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; SKIN NEOPLASMS; SKIN PIGMENTATION; SPAIN; UNITED STATES;

EID: 34547101440     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22712     Document Type: Article

References (36)

1. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22:3053-62.
2. Bressac-de-Paillerets B, Avril MF, Chompret A, Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002;84:67-74.
3. Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-de Paillerets B, Goldstein AM. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 2000;67:311-19.
4. Bishop DT, Demenais F, Goldstein AM, Bergman W, Newton Bishop J, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
5. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 2005;14:2208-12.
6. Chaudru V, Laud K, Avril M-F, Miniere A, Chompret A, Bressac-de Paillerets B, Demenais Fandthe French Familial Melanoma Study Group. Melanocortin-1 (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 2005;14:2384-90.
7. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-4.
8. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001;69:774-9.
9. Bates S, Bonetta L, Macallan D, Parry D, Holder A, Dickson C, Peters G. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 1994;9:71-9.
10. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60:249-52.
11. Kong S, Wei Q, Amos CI, Lynch PM, Levin B, Zong J, Frazier ML. Cyclin D1 Polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 2001;93:1106-8.
12. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 2002;62:3803-11.
13. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-52.
14. Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, Hemminki K. A single nucleotide polymorphism in the 3′untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 2001;95:388-93.
15. Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Zaluga E, Maleszka R, Kladny J, Gorski B, Cybulski C, Gronwald J, et al. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005;65:835-9.
16. Hosokawa Y, Tu T, Tahara H, Smith AP, Arnold A. Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett 1995;93:165-70.
17. Spica T, Portela M, Gerard B, Formicone F, Descamps V, Crickx B, Ollivaud L, Archimbaud A, Dupin N, Wolkenstein P, Vitoux D, Lebbe C, et al. The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol 2006;126:1657-60.
18. Mantelli M, Barile M, Ciotti P, Ghiorzo P, Lantieri F, Pastorino L, Catricala C, Torre GD, Folco U, Grammatico P, Padovani L, Pasini B, et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 2002;107:214-21.
19. Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F, Lynch M, Mascaro JM, Estivill X. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. Hum Genet 1997;101:359-64.
20. Ruiz A, Puig S, Malvehy J, Lazaro C, Lynch M, Gimenez-Arnau AM, Puig L, Sanchez-Conejo J, Estivill X, Castel T. CDKN2A mutations in. Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 1999;36:490-4.
21. Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonzalez U, Castel T, Campoy A, Herrero J, Marti R, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005;23:3043-51.
22. Grange F, Chompret A, Guilloud-Bataille M, Guillaume JC, Margulis A, Prade M, Demenais F, Avril MF. Comparison between familial and nonfamilial melanoma in France. Arch Dermatol 1995;131:1154-9.
23. Auroy S, Avril MF, Chompret A, Pham D, Goldstein A, Bianchi-Scarra G, Frebourg T, Joly P, Spatz A, Rubino C, Demenais F, Bressac-De Paillerets B. Sporadic mutiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 2001;32:195-202.
24. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril M-F, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004;96:785-95.
25. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in American melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92:1006-10.
26. Statxact-4, Version 4.0.1. Cambridge, MA: Cytel Software Corporation, 1989-1999.
27. Stata 8.2, Version 8.2. College Station, TX: StataCorp, Copyright, 1994-2004.
28. Pastorino L, Cusano R, Bruno W, Lantieri F, Origone P, Barile M, Gliori S, Shepherd GA, Sturm RA, Bianchi-Scarra G. Novel MC1R variants in. Ligurian melanoma patients and controls. Hum Mutat 2004;24:103.
29. Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, Swoyer J, Ter-Minassian M, Hedayati M, Grossman L, Goldstein AM, Calista D, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005;97:998-1007.
30. Fargnoli MC, Spica T, Sera F, Pellacani G, Chiarugi A, Seidenari S, Carli P, Chimenti S, Peris K. Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2006;98:144-5.
31. Fargnoli MC, Altobelli E, Keller G, Chimenti S, Hofler H, Peris K. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Melanoma Res 2006;16:175-82.
32. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86.
33. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5:1663-6.
34. Bastiaens MT, ter Huurne JA, Kielich C, Gruis NA, Westendorp RG, Vermeer BJ, Bavinck JN for the Leiden Skin Cancer Study Team. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001;68:884-94.
35. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. Melanocortin 1 receptor (MC1R) gen variants are associated with an increased risk for cutaneous melanoma wich is largely independent of skin type and hair color. J Invest Dermatol 2001;117:294-300.
36. Dwyer T, Stankovich JM, Blizzard L, FitzGerald LM, Dickinson JL, Reilly A, Williamson J, Ashbolt R, Berwick M, Sale M. Does the addition of information on genotype improve the prediction of risk of melanoma and non-melanoma skin cancer beyond that obtained from skin phenotype? Am J Epidemiol 2004;159:826-33.